The Bancroft laboratory was funded by TBVAC2020 to provide preclinical animal models to evaluate new
TB vaccine candidates.
This has yielded three
TB vaccine candidates undergoing phase IIa testing and three first - in - human trials of novel CMI - inducing adjuvants.
Since then, Aeras has helped develop 9
TB vaccine candidates and conducted over 35 Phase 1 - 2b clinical trials.
Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB) European Research Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European network of vaccine research and development TRANSVAC Advancing novel and promising
TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
NIBSC has a well - established, dedicated biological facility and relevant models for evaluating the protective potencies of BCG and new
TB vaccine candidates.
Not exact matches
Presentations will include new data from Aeras's advancing portfolio of
TB vaccines, including data from four clinical - stage
candidates.
IDRI's current
vaccine candidate (a fusion of four recombinant proteins and IDRI's proprietary adjuvant) is effective against MDR
TB strains.
They have been actively involved in finding immune correlates of protection, implementation of new
TB vaccines and testing of
vaccine candidates in murine models.
Current topics include
vaccine efficacy testing and immune correlates of
TB, AMA1 as a malaria blood stage
vaccine candidate in clinical development and development of new drugs active against malaria hypnozoites.